Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xymency
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xymency is an all-oral, twice-daily fixed-dose combination therapy developed by Bristol Myers Squibb for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Approved in Japan in December 2016, the combination consists of three direct-acting antivirals (DAAs) with distinct mechanisms of action: daclatasvir (a pangenotypic NS5A inhibitor), asunaprevir (an NS3/4A protease inhibitor), and beclabuvir (a non-nucleoside NS5B RNA-dependent RNA polymerase inhibitor). By targeting three essential viral proteins simultaneously, Xymency increases the genetic barrier to resistance and achieves high rates of sustained virologic response (SVR) in treatment-naive and interferon-experienced patients, particularly those with genotype 1b infection.
- Brand names
- Xymency
- Other names
- asunaprevir + beclabuvir + daclatasvirasunaprevir/beclabuvir/daclatasvirdaclatasvir + asunaprevir + beclabuvirdaclatasvir/asunaprevir/beclabuvir
02
Targets
NS3 (Dengue virus NS3 protein)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on Xymency.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xymency.